Results 211 to 220 of about 268,751 (268)

Isolated central nervous system relapse in mantle cell lymphoma. [PDF]

EJHaem
Chiriac R, Gross Z.
europepmc   +1 more source

Targeting the DNA damage response through TBL1X in mantle cell lymphoma. [PDF]

Blood Adv
Pray B, Baiocchi E, Leon S, Barta B, Koirala S, Tsyba L, Hinterschied C, Carvajal-Moreno J, Hout I, Nishat S, Jindal U, Jain N, Singh S, Sehgal L, Chan WK, Hanel W, Yalowich J, Baiocchi RA, Alinari L.   +18 more
europepmc   +1 more source

Ischemic Retinopathy Associated With Mantle Cell Lymphoma-Induced Vascular Occlusion. [PDF]

J Vitreoretin Dis
Turski CA, Uludag Kirimli G, Vajzovic L, Scott S, Hadziahmetovic M.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

New Directions for Mantle Cell Lymphoma in 2022.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2022
Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical.
Anita Kumar, T. Eyre, K. Lewis, Meghan C. Thompson, C. Cheah   +4 more
semanticscholar   +1 more source

Mantle cell lymphoma [PDF]

Current Treatment Options in Oncology, 2000
Mantle cell lymphoma is an aggressive non-Hodgkin's lymphoma that remains incurable with current chemotherapeutic approaches. Despite response rates to many regimens of 50% to 70%, the disease typically progresses after chemotherapy with a median survival time of approximately 3 years.
John J. Densmore, Michael E. Williams
openaire   +3 more sources